Consider Lilly: why the gloomy guidance?
This article was originally published in Scrip
Greater pessimism over generic erosion of Zyprexa sales and higher spending on SG&A are the principal reasons that Lilly's financial guidance for 2012, issued on 5 January, falls short of analyst expectations. This was the explanation given by the firm's CFO, Derica Rice, who declared that the company had already done most of its cost-cutting, having begun early (in 2004, since when net headcount has been cut by 16%) to prepare for its patent cliff moment, which it terms the 'YZ period'. This period covers the patent expiry of its top-selling antipsychotic drug Zyprexa (olanzapine) in late 2011 through to the expiry of its antidepressant drug Cymbalta (duloxetine) in the US at the end of 2013.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.